{"title":"LncRNA SDCBP2-AS1被认为是绝经后骨质疏松症的生物标志物，并通过调节miR-361-3p促进BMSCs的成骨分化。","authors":"Jindong Chen, Shilong Zhang, Dixin Cai, Qing Yin, Qian Xie, Pengfang Xu, Junling Zhu","doi":"10.1186/s41065-025-00494-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Numerous long noncoding RNAs (lncRNAs) have been proven to participate in osteogenesis and postmenopausal osteoporosis (PMOP). We measured serum SDCBP2-AS1 expression changes in patients with PMOP and investigated its effects on osteoblast differentiation in human bone marrow-derived mesenchymal stem cells (hBMSC) cells.</p><p><strong>Methods: </strong>RT-qPCR was used to measure SDCBP2-AS1 levels and the expression of osteogenic differentiation indicators. The diagnostic efficacy of SDCBP2-AS1 was assessed using a receiver operating characteristic (ROC) analysis. CCK-8 and flow cytometry methods were employed to investigate the functional impact of SDCBP2-AS1 on hBMSC cell proliferation and apoptosis during osteoblast differentiation. The bioinformatics, dual-luciferase reporter assay, and RNA Immunoprecipitation (RIP) assay were used to identify and confirm SDCBP2-AS1/miR-361-3p interaction.</p><p><strong>Results: </strong>Serum SDCBP2-AS1 was decreased in patients with PMOP, especially in those with fractures. The SDCBP2-AS1 levels were positively correlated with patients' T scores and BMDs. Decreased SDCBP2-AS1 had a certain high area under the ROC curve (AUC) value (AUC = 0.81) in distinguishing PMOP patients with fractures from those without fractures. SDCBP2-AS1 levels gradually increased after four weeks of treatment in PMOP patients and hBMSCs during cell differentiation. Enhanced SDCBP2-AS1 promoted cell proliferation and the levels of osteoblast differentiation markers, including ALP, OCN, RUNX2, and Collagen I, while decreasing cell apoptosis. miR-361-3p was a direct target of SDCBP2-AS1. The influence of SDCBP2-AS1 on cell activities and hBMSCs differentiation was diminished by miR-361-3p.</p><p><strong>Conclusions: </strong>SDCBP2-AS1 might be a diagnostic biomarker in predicting PMOP patients with fractures. By measuring the levels of SDCBP2-AS1 in patient samples, clinicians may be able to identify those who are more susceptible to bone fractures, enabling earlier and more targeted preventive measures. SDCBP2-AS1 targeting miR-361-3p regulates the osteogenic differentiation of hBMSCs, which might be a new target for the treatment of PMOP.</p>","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":"162 1","pages":"124"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247319/pdf/","citationCount":"0","resultStr":"{\"title\":\"LncRNA SDCBP2-AS1 is a putative biomarker for postmenopausal osteoporosis and promotes osteogenic differentiation of BMSCs by regulating miR-361-3p.\",\"authors\":\"Jindong Chen, Shilong Zhang, Dixin Cai, Qing Yin, Qian Xie, Pengfang Xu, Junling Zhu\",\"doi\":\"10.1186/s41065-025-00494-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Numerous long noncoding RNAs (lncRNAs) have been proven to participate in osteogenesis and postmenopausal osteoporosis (PMOP). We measured serum SDCBP2-AS1 expression changes in patients with PMOP and investigated its effects on osteoblast differentiation in human bone marrow-derived mesenchymal stem cells (hBMSC) cells.</p><p><strong>Methods: </strong>RT-qPCR was used to measure SDCBP2-AS1 levels and the expression of osteogenic differentiation indicators. The diagnostic efficacy of SDCBP2-AS1 was assessed using a receiver operating characteristic (ROC) analysis. CCK-8 and flow cytometry methods were employed to investigate the functional impact of SDCBP2-AS1 on hBMSC cell proliferation and apoptosis during osteoblast differentiation. The bioinformatics, dual-luciferase reporter assay, and RNA Immunoprecipitation (RIP) assay were used to identify and confirm SDCBP2-AS1/miR-361-3p interaction.</p><p><strong>Results: </strong>Serum SDCBP2-AS1 was decreased in patients with PMOP, especially in those with fractures. The SDCBP2-AS1 levels were positively correlated with patients' T scores and BMDs. Decreased SDCBP2-AS1 had a certain high area under the ROC curve (AUC) value (AUC = 0.81) in distinguishing PMOP patients with fractures from those without fractures. SDCBP2-AS1 levels gradually increased after four weeks of treatment in PMOP patients and hBMSCs during cell differentiation. Enhanced SDCBP2-AS1 promoted cell proliferation and the levels of osteoblast differentiation markers, including ALP, OCN, RUNX2, and Collagen I, while decreasing cell apoptosis. miR-361-3p was a direct target of SDCBP2-AS1. The influence of SDCBP2-AS1 on cell activities and hBMSCs differentiation was diminished by miR-361-3p.</p><p><strong>Conclusions: </strong>SDCBP2-AS1 might be a diagnostic biomarker in predicting PMOP patients with fractures. By measuring the levels of SDCBP2-AS1 in patient samples, clinicians may be able to identify those who are more susceptible to bone fractures, enabling earlier and more targeted preventive measures. SDCBP2-AS1 targeting miR-361-3p regulates the osteogenic differentiation of hBMSCs, which might be a new target for the treatment of PMOP.</p>\",\"PeriodicalId\":12862,\"journal\":{\"name\":\"Hereditas\",\"volume\":\"162 1\",\"pages\":\"124\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247319/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hereditas\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1186/s41065-025-00494-5\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-025-00494-5","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LncRNA SDCBP2-AS1 is a putative biomarker for postmenopausal osteoporosis and promotes osteogenic differentiation of BMSCs by regulating miR-361-3p.
Background: Numerous long noncoding RNAs (lncRNAs) have been proven to participate in osteogenesis and postmenopausal osteoporosis (PMOP). We measured serum SDCBP2-AS1 expression changes in patients with PMOP and investigated its effects on osteoblast differentiation in human bone marrow-derived mesenchymal stem cells (hBMSC) cells.
Methods: RT-qPCR was used to measure SDCBP2-AS1 levels and the expression of osteogenic differentiation indicators. The diagnostic efficacy of SDCBP2-AS1 was assessed using a receiver operating characteristic (ROC) analysis. CCK-8 and flow cytometry methods were employed to investigate the functional impact of SDCBP2-AS1 on hBMSC cell proliferation and apoptosis during osteoblast differentiation. The bioinformatics, dual-luciferase reporter assay, and RNA Immunoprecipitation (RIP) assay were used to identify and confirm SDCBP2-AS1/miR-361-3p interaction.
Results: Serum SDCBP2-AS1 was decreased in patients with PMOP, especially in those with fractures. The SDCBP2-AS1 levels were positively correlated with patients' T scores and BMDs. Decreased SDCBP2-AS1 had a certain high area under the ROC curve (AUC) value (AUC = 0.81) in distinguishing PMOP patients with fractures from those without fractures. SDCBP2-AS1 levels gradually increased after four weeks of treatment in PMOP patients and hBMSCs during cell differentiation. Enhanced SDCBP2-AS1 promoted cell proliferation and the levels of osteoblast differentiation markers, including ALP, OCN, RUNX2, and Collagen I, while decreasing cell apoptosis. miR-361-3p was a direct target of SDCBP2-AS1. The influence of SDCBP2-AS1 on cell activities and hBMSCs differentiation was diminished by miR-361-3p.
Conclusions: SDCBP2-AS1 might be a diagnostic biomarker in predicting PMOP patients with fractures. By measuring the levels of SDCBP2-AS1 in patient samples, clinicians may be able to identify those who are more susceptible to bone fractures, enabling earlier and more targeted preventive measures. SDCBP2-AS1 targeting miR-361-3p regulates the osteogenic differentiation of hBMSCs, which might be a new target for the treatment of PMOP.
HereditasBiochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.80
自引率
3.70%
发文量
0
期刊介绍：
For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
